Neurizon Therapeutics (ASX:NUZ) received a US Patent for the use of its neurodegenerative diseases and cancer drug candidate NUZ-001, the company said in a Wednesday Australian bourse filing.
The patent provides protection for NUZ-001 and related compounds used in treatments for mTOR pathway-related diseases in the US market until 2039, added the filing.
Neurizon Therapeutics' shares were up 16% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.